Published in Medical Verdicts and Law Weekly, May 10th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at UCB Pharma.
Report 1: The US Food and Drug Administration (FDA) has approved UCB's leading anti-epileptic drug Keppra(R) (levetiracetam), as adjunctive therapy in the treatment of primary generalized tonic-clonic (PGTC) seizures in adults and children 6 years of age and older with idiopathic generalised epilepsy (IGE). In epidemiological studies generalized seizures account for about 40% of incidence cases, with generalized tonic-clonic seizures estimated at 23%.1 The new indication, which is the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Verdicts and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.